Journal of Pharmacology and Experimental Therapeutics (JPET) is one of the leading journals serving the membership of the American Society for Pharmacology and Experimental Therapeutics (ASPET). JPET focuses on the publication of important and ground-breaking innovative science. We publish original research papers and minireviews dealing with interactions of chemicals with biologic systems. All aspects of pharmacology and therapeutics are within the scope of the Journal. Ensuring the highest scientific quality of JPET depends on the hard work of the editor-in-chief, senior associate editors, editorial advisory board members, and reviewers who give so much time to the journal. Effective, fair, and timely reviews of submitted manuscripts are critical for the vibrancy of JPET. We want to take this opportunity to thank all of you who have been involved in the JPET scientific manuscript review process by providing your expertise as a reviewer. Taken together, each of you has provided dedicated scientific service. It is also our pleasure to recognize Mahmood S. Mozaffari for his ASPET Best Reviewer Award. He handled many submissions efficiently and provided consistently high-quality, thoughtful, and constructive recommendation summaries to the authors.As we start the new year, we would like to share with you the latest additions to JPET that we hope will address the future needs of our authors and editors. We have addressed the need to improve the author experience and enhance experimental rigor and reproducibility by adding a simplified author checklist to promote experimental rigor and reproducibility (Table 1).
New and Improved Article TypesViewpoint. We have introduced a new article type called Viewpoint (Greenwood-Van Meerveld, 2022) that was introduced to broaden the scientific content of JPET by inviting an author to present a new or unique perspective on a manuscript recently accepted for publication in JPET. The initial goal is to publish at least one Viewpoint per issue coupled with the editorialized article. Recently, due to the interest received, some issues will include two Viewpoints. Viewpoint articles may comment on existing problems, highlight current advances, and briefly speculate future directions of the topic or provide other points of view. The first Viewpoint by Avvisato et al. ( 2023) was published in January 2023.Minireviews. JPET continues to publish Minireviews as a platform for discussing concepts and topics of importance and relevance to pharmacology. Minireview submissions may be invited or unsolicited, and JPET encourages those interested in preparing a Minireview manuscript to complete a Presubmission Inquiry to determine whether the topic lies within the scope of the journal. The JPET Minireview guidelines for authors were revised and updated in July 2023 to provide additional guidance in preparing Minireview manuscripts. Page charges are waived for Minireview submissions.JPET recently launched a new Minireview initiative together with the ASPET Young Scientist Committee to foster the r...
